# LigaChem Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ligachem-biosciences

- Industry: Pharmaceuticals
- Headquarters: Daejeon, South Korea
- Website: www.ligachembio.com
- Total disclosed funding: $13M
- Latest round: Series D (Nov 5, 2012)
- Investors on record: 4

## About

Founded in 2006 and based in Daejeon, South Korea, LigaChem Biosciences Inc. is a research-oriented pharmaceutical company. The company was founded by its CEO, Kim Yong-ju. In January 2024, Lego Chem Biosciences raised KRW 550 billion in venture funding from Pan Orion. Following the transaction, Pan Orion will own a 4.93% minority stake in the company. The transaction includes 1.2 million shares previously owned by Lego Chem Biosciences' management.

Ligachem's core technology, LigaChemistry, is a drug discovery platform used to develop new drug candidates in areas such as antibiotics, anti-fibrotics, immuno-oncology, and anticoagulants. The company also specializes in providing antibody-drug conjugates (ADCs) through its ConjuALL platform.

## Funding rounds

- Series D, Nov 5, 2012, $1.8M — Atinum Investment
- Series C, Dec 28, 2011, $3M — Atinum Investment
- Series B, Jul 14, 2009, $3.1M — Atinum Investment, Korea Investment Partners
- Series A, Apr 1, 2007, $4.8M — Atinum Investment, Yuanta Investment, KDB Capital

## Investors

- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A, Series B, Series C, Series D
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series A
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B